This document describes outcomes from an ambulatory allografting program for high-risk multiple myeloma patients. 71 patients received tandem autologous stem cell transplants followed by a non-myeloablative allogeneic stem cell transplant. Results showed acceptable toxicity and transplant-related mortality. Higher CD3 cell doses in the allograft were associated with better donor chimerism and outcomes. Achieving a complete or stringent complete response after transplantation correlated with improved progression-free and overall survival. Upfront tandem transplants in high-risk patients showed similar or better survival compared to upfront autologous transplant alone in standard-risk patients.
Conférence du Dr. Maximiliano GELLI (Chirurgien hépatique, AP-HP Hôpital Paul Brousse, Villejuif, France) aux Journées de Chirurgie Hépato-Biliaire, juin 2014, Paris.
The detrimental effects of Donor Specific HLA alloantibodies (DSA) on outcomes following liver organ transplantation have been known for many years.
Liver transplantation is an exception but some evidence has been recently highlighted, showing that DSA could be associated with acute antibody-mediated rejection, chronic rejection, plasma cell hepatitis, anastomotic biliary stricture, NRH, fibrosis progression... The prevalence of preformed donor specific DSA is about 20% and the incidence of de novo DSA is about 10% in Liver transplantation (LT). DSA are associated with several graft diseases, mainly AMR but diagnosis was made on histological features+/-C4d staining. De novo DSA and preformed class II DSA, especially with high MFI, seem to pejoratively influence outcomes after LT. When associated with HCV, DSA worsen fibrosis progression. Thanks to antiviral IFN-free regimen, therapeutic strategies of DSA positivity and/or AMR will not differ from HCV- recipients, but need to be evaluated in prospective studies.
Conférence du Dr. Maximiliano GELLI (Chirurgien hépatique, AP-HP Hôpital Paul Brousse, Villejuif, France) aux Journées de Chirurgie Hépato-Biliaire, juin 2014, Paris.
The detrimental effects of Donor Specific HLA alloantibodies (DSA) on outcomes following liver organ transplantation have been known for many years.
Liver transplantation is an exception but some evidence has been recently highlighted, showing that DSA could be associated with acute antibody-mediated rejection, chronic rejection, plasma cell hepatitis, anastomotic biliary stricture, NRH, fibrosis progression... The prevalence of preformed donor specific DSA is about 20% and the incidence of de novo DSA is about 10% in Liver transplantation (LT). DSA are associated with several graft diseases, mainly AMR but diagnosis was made on histological features+/-C4d staining. De novo DSA and preformed class II DSA, especially with high MFI, seem to pejoratively influence outcomes after LT. When associated with HCV, DSA worsen fibrosis progression. Thanks to antiviral IFN-free regimen, therapeutic strategies of DSA positivity and/or AMR will not differ from HCV- recipients, but need to be evaluated in prospective studies.
Join Dr. Emily Chan presentation on the latest research and treatments for colorectal cancer patients presented at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.
David R. Jones, MD, and Roy S. Herbst, MD, PhD, prepared useful practice aids pertaining to lung cancer for this CME activity titled "Turning Tides in Targeted Therapy for Early-Stage EGFR-Mutated NSCLC: Latest Data and Practical Guidance for Thoracic Surgeons and the Multidisciplinary Team on the Emerging Role of EGFR-Targeted Therapy in Resectable Lung Cancer." For the full presentation, complete CME information, and to apply for credit, please visit us at https://bit.ly/2PSVELG. CME credit will be available until November 9, 2021.
Conférence du Professeur Philippe Mathurin (Hôpital Universitaire Claure Huriez, Lille, France), Juin 2014. Le "Binge Drinking" est un des enjeux de santé publique majeur dans tous les pays occidentaux. Une augmentation de la mortalité par cirrhose alcoolique est constatée dans les pays où l'alcoolisme chronique et le Binge Drinking sont les plus répandus.
Ponencia sobre 'Enfermedad valvular e intervencionismo', presentada por el Dr. Tomás Ripoll en el directo online 'Lo mejor del ACC 2014', celebrado en la Casa del Corazón.
Presentación "Manejo de la antiagregación ajustada a las pruebas de reactividad plaquetaria. Experiencia, Resultados y futuro de un programa nacional" del Dr. Daniel Aradi durante la Mesa Redonda de Antiagregación de la XXV Reunión Anual de la Sección de Hemodinámica y Cardiología Intervencionista (SHCI) de 2014 en Córdoba.
Join Dr. Emily Chan presentation on the latest research and treatments for colorectal cancer patients presented at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.
David R. Jones, MD, and Roy S. Herbst, MD, PhD, prepared useful practice aids pertaining to lung cancer for this CME activity titled "Turning Tides in Targeted Therapy for Early-Stage EGFR-Mutated NSCLC: Latest Data and Practical Guidance for Thoracic Surgeons and the Multidisciplinary Team on the Emerging Role of EGFR-Targeted Therapy in Resectable Lung Cancer." For the full presentation, complete CME information, and to apply for credit, please visit us at https://bit.ly/2PSVELG. CME credit will be available until November 9, 2021.
Conférence du Professeur Philippe Mathurin (Hôpital Universitaire Claure Huriez, Lille, France), Juin 2014. Le "Binge Drinking" est un des enjeux de santé publique majeur dans tous les pays occidentaux. Une augmentation de la mortalité par cirrhose alcoolique est constatée dans les pays où l'alcoolisme chronique et le Binge Drinking sont les plus répandus.
Ponencia sobre 'Enfermedad valvular e intervencionismo', presentada por el Dr. Tomás Ripoll en el directo online 'Lo mejor del ACC 2014', celebrado en la Casa del Corazón.
Presentación "Manejo de la antiagregación ajustada a las pruebas de reactividad plaquetaria. Experiencia, Resultados y futuro de un programa nacional" del Dr. Daniel Aradi durante la Mesa Redonda de Antiagregación de la XXV Reunión Anual de la Sección de Hemodinámica y Cardiología Intervencionista (SHCI) de 2014 en Córdoba.
5-Year Survival of Non-Small Cell Lung Cancer Patients after Radical Surgery Significantly Depended on Phase Transition “Early-Invasive Cancer”, Lymph Node Metastases and Cell Ratio Factors
5-YEAR SURVIVAL OF UPPER THIRD ESOPHAGEAL CANCER PATIENTS WAS SIGNIFICANTLY SUPERIOR IN COMPARISON WITH MIDDLE AND LOWER THIRD ESOPHAGEAL CANCER PATIENTS AFTER RADICAL SURGERY AND STRONGLY DEPENDED ON PHASE TRANSITION EARLY-INVASIVE CANCER, LYMPH NODE METASTASES, CELL RATIO FACTORS AND ADJUVANT CHEMOIMMUNORADIOTHERAPY
FACTORS AFFECTING INITIAL CYCLOSPORINE A LEVEL AND ITS CORRELATION WITH CLINI...Alok Gupta
FACTORS AFFECTING INITIAL CYCLOSPORINE A LEVEL AND ITS CORRELATION WITH CLINICAL OUTCOME INACUTE LEUKEMIA PATIENTS UNDERGOING ALLOGENEIC STEM CELL TRANSPLANTATION
HWANG Chung Cheng Jordan, RN, MN, Adv. Dip. (Oncology),
Advanced Practice Nurse – Haematology
Division of Nursing
Department of Haematology
Singapore General Hospital, Singapore
30th October 2016
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?bkling
Are you curious about what’s new in cervical cancer research or unsure what the findings mean? Join Dr. Emily Ko, a gynecologic oncologist at Penn Medicine, to learn about the latest updates from the Society of Gynecologic Oncology (SGO) 2024 Annual Meeting on Women’s Cancer. Dr. Ko will discuss what the research presented at the conference means for you and answer your questions about the new developments.
Explore natural remedies for syphilis treatment in Singapore. Discover alternative therapies, herbal remedies, and lifestyle changes that may complement conventional treatments. Learn about holistic approaches to managing syphilis symptoms and supporting overall health.
Acute scrotum is a general term referring to an emergency condition affecting the contents or the wall of the scrotum.
There are a number of conditions that present acutely, predominantly with pain and/or swelling
A careful and detailed history and examination, and in some cases, investigations allow differentiation between these diagnoses. A prompt diagnosis is essential as the patient may require urgent surgical intervention
Testicular torsion refers to twisting of the spermatic cord, causing ischaemia of the testicle.
Testicular torsion results from inadequate fixation of the testis to the tunica vaginalis producing ischemia from reduced arterial inflow and venous outflow obstruction.
The prevalence of testicular torsion in adult patients hospitalized with acute scrotal pain is approximately 25 to 50 percent
Ethanol (CH3CH2OH), or beverage alcohol, is a two-carbon alcohol
that is rapidly distributed in the body and brain. Ethanol alters many
neurochemical systems and has rewarding and addictive properties. It
is the oldest recreational drug and likely contributes to more morbidity,
mortality, and public health costs than all illicit drugs combined. The
5th edition of the Diagnostic and Statistical Manual of Mental Disorders
(DSM-5) integrates alcohol abuse and alcohol dependence into a single
disorder called alcohol use disorder (AUD), with mild, moderate,
and severe subclassifications (American Psychiatric Association, 2013).
In the DSM-5, all types of substance abuse and dependence have been
combined into a single substance use disorder (SUD) on a continuum
from mild to severe. A diagnosis of AUD requires that at least two of
the 11 DSM-5 behaviors be present within a 12-month period (mild
AUD: 2–3 criteria; moderate AUD: 4–5 criteria; severe AUD: 6–11 criteria).
The four main behavioral effects of AUD are impaired control over
drinking, negative social consequences, risky use, and altered physiological
effects (tolerance, withdrawal). This chapter presents an overview
of the prevalence and harmful consequences of AUD in the U.S.,
the systemic nature of the disease, neurocircuitry and stages of AUD,
comorbidities, fetal alcohol spectrum disorders, genetic risk factors, and
pharmacotherapies for AUD.
micro teaching on communication m.sc nursing.pdfAnurag Sharma
Microteaching is a unique model of practice teaching. It is a viable instrument for the. desired change in the teaching behavior or the behavior potential which, in specified types of real. classroom situations, tends to facilitate the achievement of specified types of objectives.
New Drug Discovery and Development .....NEHA GUPTA
The "New Drug Discovery and Development" process involves the identification, design, testing, and manufacturing of novel pharmaceutical compounds with the aim of introducing new and improved treatments for various medical conditions. This comprehensive endeavor encompasses various stages, including target identification, preclinical studies, clinical trials, regulatory approval, and post-market surveillance. It involves multidisciplinary collaboration among scientists, researchers, clinicians, regulatory experts, and pharmaceutical companies to bring innovative therapies to market and address unmet medical needs.
Title: Sense of Smell
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the primary categories of smells and the concept of odor blindness.
Explain the structure and location of the olfactory membrane and mucosa, including the types and roles of cells involved in olfaction.
Describe the pathway and mechanisms of olfactory signal transmission from the olfactory receptors to the brain.
Illustrate the biochemical cascade triggered by odorant binding to olfactory receptors, including the role of G-proteins and second messengers in generating an action potential.
Identify different types of olfactory disorders such as anosmia, hyposmia, hyperosmia, and dysosmia, including their potential causes.
Key Topics:
Olfactory Genes:
3% of the human genome accounts for olfactory genes.
400 genes for odorant receptors.
Olfactory Membrane:
Located in the superior part of the nasal cavity.
Medially: Folds downward along the superior septum.
Laterally: Folds over the superior turbinate and upper surface of the middle turbinate.
Total surface area: 5-10 square centimeters.
Olfactory Mucosa:
Olfactory Cells: Bipolar nerve cells derived from the CNS (100 million), with 4-25 olfactory cilia per cell.
Sustentacular Cells: Produce mucus and maintain ionic and molecular environment.
Basal Cells: Replace worn-out olfactory cells with an average lifespan of 1-2 months.
Bowman’s Gland: Secretes mucus.
Stimulation of Olfactory Cells:
Odorant dissolves in mucus and attaches to receptors on olfactory cilia.
Involves a cascade effect through G-proteins and second messengers, leading to depolarization and action potential generation in the olfactory nerve.
Quality of a Good Odorant:
Small (3-20 Carbon atoms), volatile, water-soluble, and lipid-soluble.
Facilitated by odorant-binding proteins in mucus.
Membrane Potential and Action Potential:
Resting membrane potential: -55mV.
Action potential frequency in the olfactory nerve increases with odorant strength.
Adaptation Towards the Sense of Smell:
Rapid adaptation within the first second, with further slow adaptation.
Psychological adaptation greater than receptor adaptation, involving feedback inhibition from the central nervous system.
Primary Sensations of Smell:
Camphoraceous, Musky, Floral, Pepperminty, Ethereal, Pungent, Putrid.
Odor Detection Threshold:
Examples: Hydrogen sulfide (0.0005 ppm), Methyl-mercaptan (0.002 ppm).
Some toxic substances are odorless at lethal concentrations.
Characteristics of Smell:
Odor blindness for single substances due to lack of appropriate receptor protein.
Behavioral and emotional influences of smell.
Transmission of Olfactory Signals:
From olfactory cells to glomeruli in the olfactory bulb, involving lateral inhibition.
Primitive, less old, and new olfactory systems with different path
Prix Galien International 2024 Forum ProgramLevi Shapiro
June 20, 2024, Prix Galien International and Jerusalem Ethics Forum in ROME. Detailed agenda including panels:
- ADVANCES IN CARDIOLOGY: A NEW PARADIGM IS COMING
- WOMEN’S HEALTH: FERTILITY PRESERVATION
- WHAT’S NEW IN THE TREATMENT OF INFECTIOUS,
ONCOLOGICAL AND INFLAMMATORY SKIN DISEASES?
- ARTIFICIAL INTELLIGENCE AND ETHICS
- GENE THERAPY
- BEYOND BORDERS: GLOBAL INITIATIVES FOR DEMOCRATIZING LIFE SCIENCE TECHNOLOGIES AND PROMOTING ACCESS TO HEALTHCARE
- ETHICAL CHALLENGES IN LIFE SCIENCES
- Prix Galien International Awards Ceremony
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...kevinkariuki227
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...Oleg Kshivets
RESULTS: Overall life span (LS) was 2252.1±1742.5 days and cumulative 5-year survival (5YS) reached 73.2%, 10 years – 64.8%, 20 years – 42.5%. 513 LCP lived more than 5 years (LS=3124.6±1525.6 days), 148 LCP – more than 10 years (LS=5054.4±1504.1 days).199 LCP died because of LC (LS=562.7±374.5 days). 5YS of LCP after bi/lobectomies was significantly superior in comparison with LCP after pneumonectomies (78.1% vs.63.7%, P=0.00001 by log-rank test). AT significantly improved 5YS (66.3% vs. 34.8%) (P=0.00000 by log-rank test) only for LCP with N1-2. Cox modeling displayed that 5YS of LCP significantly depended on: phase transition (PT) early-invasive LC in terms of synergetics, PT N0—N12, cell ratio factors (ratio between cancer cells- CC and blood cells subpopulations), G1-3, histology, glucose, AT, blood cell circuit, prothrombin index, heparin tolerance, recalcification time (P=0.000-0.038). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and PT early-invasive LC (rank=1), PT N0—N12 (rank=2), thrombocytes/CC (3), erythrocytes/CC (4), eosinophils/CC (5), healthy cells/CC (6), lymphocytes/CC (7), segmented neutrophils/CC (8), stick neutrophils/CC (9), monocytes/CC (10); leucocytes/CC (11). Correct prediction of 5YS was 100% by neural networks computing (area under ROC curve=1.0; error=0.0).
CONCLUSIONS: 5YS of LCP after radical procedures significantly depended on: 1) PT early-invasive cancer; 2) PT N0--N12; 3) cell ratio factors; 4) blood cell circuit; 5) biochemical factors; 6) hemostasis system; 7) AT; 8) LC characteristics; 9) LC cell dynamics; 10) surgery type: lobectomy/pneumonectomy; 11) anthropometric data. Optimal diagnosis and treatment strategies for LC are: 1) screening and early detection of LC; 2) availability of experienced thoracic surgeons because of complexity of radical procedures; 3) aggressive en block surgery and adequate lymph node dissection for completeness; 4) precise prediction; 5) adjuvant chemoimmunoradiotherapy for LCP with unfavorable prognosis.
Couples presenting to the infertility clinic- Do they really have infertility...Sujoy Dasgupta
Dr Sujoy Dasgupta presented the study on "Couples presenting to the infertility clinic- Do they really have infertility? – The unexplored stories of non-consummation" in the 13th Congress of the Asia Pacific Initiative on Reproduction (ASPIRE 2024) at Manila on 24 May, 2024.
Ocular injury ppt Upendra pal optometrist upums saifai etawah
Andrew Spencer - Outcomes of an Ambulatory Allografting Programme for Adverse Risk Multiple Myeloma
1. Outcomes of an Ambulatory Allografting
Programme for Adverse Risk Multiple
Myeloma
Prof Andrew Spencer
Myeloma Research Group,
Division of Blood Cancers,
Alfred Hospital & Monash University,
Melbourne, Australia
3. 0%
25%
50%
75%
100%
0 10 20 30 40 50
Time (months)
Multiple myelomaOverall Survival
Almost 25% of Australian MM patients die
within 2 years of diagnosis.Conversely,
a similar proportion are expected to survive
> 10 years reflecting marked heterogeneity
in disease biology
0
200
400
600
800
1000
1200
Caseaccrual
27mar2013 13nov2013 3jul2014 19feb2015 9oct2015 27may2016
Date
4. Moreau P et al. JCO 2014;32:2173-2180
Overall survival for 1,601 patients with lactate
dehydrogenase, International Staging System, and
cytogenetic data available.
Death within 2 years from progressive MM
• Stage 3 ISS
• LDH > normal
• Adverse FISH*
Adverse FISH = t(4;14) and/or 17p-
6. Transplant period and
stem cell source
TRM at 6 months (%) TRM at 2 yrs (%)
1983-93
BM
38 46
1994-1998
BM
21 30
1994-1998
PBSC
25 37
From EBMT registry. Br.J Haematol 2001; 113(1):209
UnacceptableTRM with MAB allografting
7. RIC vs MAB comparison
• EBMT data, 320 RIC vs 196 MABTx between 1998 & 2002
• RIC patients were older 51yrs vs 45yrs with more progressive disease (28%
vs 21%) and more priorASCT (76%Vs 11%)
• RIC patients had longer time to transplant and more received PBSC.
• NRM at 2yrs, RIC vs MAB=24% vs 37% (p=.002).
• OS=38.1% vs 50.8% (ns), PFS=18.9% vs 34.5% (p=.001).
• On multivariate analysis RIC associated with reduction in NRM (HR-0.5), but
increased relapse (HR-2)
Blood 2007;109(8)
8. Tandem Transplant vs RIC Allograft
(a) OS (b) PFS (c) relapse/progression (d) NRM
BMT 2015; 50, 802-807
9. TandemASCT-NMA
• Tandem Auto-NMA. Related or unrelated donors. Age to 70
years.
• Upfront (de novo MM) and deferred (relapsed) patient groups.
• At least PR prior to NMA SCT with no evidence of disease
progression.
• Strict eligibility criteria for upfront treatment – at least 2 of the
following:
Stage 3 ISS
FISH – 17p-, t(4;14), 1q+
High LDH
Abnormal cytogenetics
PCL/EMD
Suboptimal induction response – IMID or PI-based.
At diagnosis
10. • Fludarabine 48mg/m2 PO days -4 to -2.
• 2Gy TBI day 0.
• Cell dose 2 x 106 CD34/kg.
• Cyclosporin/MMF.
• Ciprofloxacin – Neut <0.5.
• No anti-fungal/CMV prophylaxis – weekly Q-PCR CMV.
• PCP/VZV prophylaxis.
FludarabineTBI protocol
Registrar review - HOC thrice weekly
Consultant review dedicated MM clinic - weekly
First NMA January 2008
11. TANDEM ASCT/NMA HSCT IN MULTIPLE MYELOMA
Patient and Disease Characteristics
Upfront tandem
ASCT/NMA HSCT
Deferred tandem
ASCT/NMA HSCT
Overall
Number of Patients 33 38 71
Patient Age, median (range) 52 (22-66) 56 (32-67) 55 (22-66)
Patient Gender (M/F) 16/17 26/12 42/29
Donor:
Sibling
Unrelated
11
22
16
22
27
44
Disease Status at HSCT:
AT ALLOHSCT
CR
VGPR
PR
SD
PD
11
7
14
1
0
13
2
17
5
1
24
9
31
6
1
Days ASCT to alloHSCT, median(range) 98 (63-318) 92.5 (50-336) 96 (50-336)
12. TANDEM ASCT/NMA HSCT IN MULTIPLE MYELOMA
Day 30 and Day 100 Admission Data
Upfront
tandem
ASCT/NMA
HSCT
Deferred
tandem
ASCT/NMA
HSCT
Overall
Number of Patients 33 38 71
Outpatient Transplants 29 33 62 (87%)
ADMISSIONS WITHIN 30 DAYS #
Admissions
#
Admissions
#
Admissions
Nil Admissions 14 13 27
Median (Days) 10 8 9
Range (Days) (1-71) (1-26) (1-71)
REASON FOR ADMISSION:
Elective Admission (Inpatient transplants) 3 5 8
Fevers/Infection 3 6 9
Infusion Reaction/Observation 4 9 13
Fever of Unknown Origin / noninfective 6 4 10
GVHD 3 4 7
Other
Median # days per admission:
7
7.5 (1-68)
6
5.5 (1-15)
13
ADMISSIONS WITHIN 100 DAYS #
Admissions
#
Admissions
#
Admissions
Nil Admissions 13 7 20
Median (Days) 14 9 11
Range (Days) (1-120) (1-34) (1-120)
REASON FOR ADMISSION:
Elective Admission (Inpatient transplants) 3 5 8
Fevers/Infection 7 13 20
Infusion Reaction/Observation 4 9 13
Fever of Unknown Origin /noninfective 8 6 14
GVHD 5 6 11
Other 9 9 18
13. TANDEM ASCT/NMA HSCT IN MULTIPLE MYELOMA
Day 30 and Day 100 Admission Data
Upfront
tandem
ASCT/NMA
HSCT
Deferred
tandem
ASCT/NMA
HSCT
Overall
Number of Patients 33 38 71
Outpatient Transplants 29 33 62 (87%)
ADMISSIONS WITHIN 30 DAYS #
Admissions
#
Admissions
#
Admissions
Nil Admissions 14 13 27
Median (Days) 10 8 9
Range (Days) (1-71) (1-26) (1-71)
REASON FOR ADMISSION:
Elective Admission (Inpatient transplants) 3 5 8
Fevers/Infection 3 6 9
Infusion Reaction/Observation 4 9 13
Fever of Unknown Origin / noninfective 6 4 10
GVHD 3 4 7
Other
Median # days per admission:
7
7.5 (1-68)
6
5.5 (1-15)
13
ADMISSIONS WITHIN 100 DAYS #
Admissions
#
Admissions
#
Admissions
Nil Admissions 13 7 20
Median (Days) 14 9 11
Range (Days) (1-120) (1-34) (1-120)
REASON FOR ADMISSION:
Elective Admission (Inpatient transplants) 3 5 8
Fevers/Infection 7 13 20
Infusion Reaction/Observation 4 9 13
Fever of Unknown Origin /noninfective 8 6 14
GVHD 5 6 11
Other 9 9 18
14. TANDEM ASCT/NMA HSCT IN MULTIPLE MYELOMA
Outcomes
ENGRAFTMENT POST NMA HSCT
Upfront tandem
ASCT/NMA HSCT
Deferred tandem
ASCT/NMA HSCT
Overall
NEUTROPHILS>0.5x109
/L
Median 0 16.5 11
Range (0-25) (0-26) (0-26)
Never below 17 (52%) 12 (32%) 26 (41%)
NEUTROPHILS>1.0x109
/L
Median 21 20 20
Range (0-35) (0-85) (0-85)
Never below 3 (9%) 3 (8%) 6 (8%)
PLATELETS>20x109
/L
Median 0 0 0
Range (0-11) (0-17) (0-17)
Never below 32 (97%) 34 (89%) 36 (93%)
PLATELETS>50x109
/L
Median 0 0 0
Range (0-18) (0-18) (0-18)
Never below 25 (76%) 28 (74%) 53 (75%)
GVHD
GVHD
GVHD Upfront tandem
ASCT/NMA HSCT
Deferred tandem
ASCT/NMA HSCT
Overall
ASCT/NMA HSCT ASCT/NMA HSCT
AGVHD
Nil 17 19 36
Grade I 8 5 13
Grade II 2 10 12
Grade III 4 3 7
Grade IV 2 1 3
% Grade II_IV 24% 37% 31%
CGVHD
Nil 11 20 31
Limited 2 5 7
Extensive 16 6 32
Not evaluable 4 7 11
15. TANDEM ASCT/NMA HSCT IN MULTIPLE MYELOMA
Outcomes
OUTCOMES Upfront Tandem
ASCT/NMA
HSCT
Deferred
Tandem
ASCT/NMA
HSCT
Overall
NUMBER OF PATIENTS 33 38 71
BEST DISEASE RESPONSE POST ALLOHSCT
CR/sCR 18 20 38
VGPR 2 3 5
PR 2 4 6
SD 3 1 4
PD 5 7 12
Not yet achieved 3 3 6
PROGRESSION 13 (39%) 17 (45%) 30 (42%)
TRANSPLANT RELATED MORTALITY
CAUSE OF DEATH
Primary Disease
GVHD
Infection
6
4
4
2
2
10
1
1
8
13
5
4
14
3
16. TANDEM ASCT/NMA HSCT IN MULTIPLE MYELOMA
Comparison of Overall and Progression Free Survival
0.00
0.20
0.40
0.60
0.80
1.00
OverallSurvivalProbability
0 2 4 6 8 10
Years post ASCT
Deferred Tandem ASCT/NMA HSCT
Upfront Tandem ASCT/NMA HSCT
Overall Survival - Upfront versus Deferred Tandem ASCT/NMA HSCT
SURVIVAL OUTCOME UPFRONT TANDEM
ASCT/NMA HSCT
DEFERRED TANDEM
ASCT/NMA HSCT
OVERALL SURVIVAL % %
3 YEARS 66 62
5 YEARS 61 53
PROGRESSION FREE SURVIVAL
3 YEARS 42 44
5 YEARS 34 33
0.00
0.20
0.40
0.60
0.80
1.00
ProgressionFreeSurvivalProbability
0 2 4 6 8 10
Years post ASCT
Deferred Tandem ASCT/NMA HSCT
Upfront Tandem ASCT/NMA HSCT
Progression Free Survival - Upfront versus Deferred Tandem ASCT/NMA HSCT
17. TANDEM ASCT/NMA HSCT IN MULTIPLE MYELOMA
Cumulative Incidence of Progression and Non relapse Mortality
Non-relapse Mortality
Upfront versus Deferred Tandem ASCT/NMA HSCT
CUMULATIVE INCIDENCE UPFRONT TANDEM
ASCT/NMA HSCT
DEFERRED TANDEM
ASCT/NMA HSCT
CI OF PROGRESSION % %
3 YEARS 38 49
5 YEARS 46 60
NON RELAPSE MORTALITY
3 YEARS 20 7
5 YEARS 20 7
Cumulative Incidence of Progression-
Upfront versus Deferred Tandem ASCT/NMA HSCT
18. UPFRONT TANDEM ASCT/NMA HSCT (HR MM) vs UPFRONT
ASCT (SR MM)
Comparison of Overall and Progression Free Survival
0.00
0.20
0.40
0.60
0.80
1.00
ProgressionFreeSurvival
0 2 4 6 8 10
Years
Upfront ASCT
Upfront tandem ASCT/NMA HSCT
Progression Free Survival - Upfront Tandem ASCT/NMA vs Upfront ASCT
SURVIVAL OUTCOME
UPFRONT TANDEM
ASCT/NMA HSCT
UPFRONT ASCT
OVERALL SURVIVAL % %
3 YEARS 66 77
5 YEARS 61 67
PROGRESSION FREE SURVIVAL
3 YEARS 42 49
5 YEARS 34 24
0.00
0.20
0.40
0.60
0.80
1.00
OverallSurvival
0 2 4 6 8 10
Years
Upfront ASCT
Upfront Tandem ASCT/NMA HSCT
Overall Survival-Upfront Tandem ASCT/NMA HSCT versus Upfront ASCT
19. Endpoint Factor HR (CI) p value
PFS Prior lines (>3 vs 1-3) 4.76 (2.07-10.96) 0.0002
ISS (3 vs 1-2) 2.97 (1.17-7.55) 0.02
Best response post tandem
(<CR vs CR vs sCR)
4.17 (2.37-7.36) <0.0001
OS
Best response post tandem
(<CR vs CR vs sCR)
5.54 (2.67-11.5) <0.0001
CD3 cell dose (<3 or ≥3 x 108/kg
)
1.42 (1.21-1.67) <0.0001
Risk of
progression
Prior lines (>3 vs 1-3) 3.00 (1.28-7.04) 0.01
Best response post tandem
(<CR vs CR vs sCR)
3.10 (1.52-6.35) 0.002
SIGNIFICANT FACTORS ON MULTIVARIATE ANALYSIS
n = 59, median F/U 48 months
20. N = 33
p = 0.0004
OS BASED ON BEST RESPONSE POST-NMA
22. 30 60 90 180
85
90
95
100
Days post allo-HSCT
Mean%
Dynamics of CD3+
Donor Chimerism in a cohort (n = 54)
Days post-NMA
CD3 DOSE vs CHIMAERISM TO DAY+180
25. 0.00
0.20
0.40
0.60
0.80
1.00
0 2 4 6 8 10
Years
NMA 2008-Nov 2015
NMA Dec 2015-September 2016
Overall Survival
TANDEM ASCT/NMA HSCT IN MULTIPLE MYELOMA
Overall Survival – upfront plus deferred
26. Summary
Tandem ASCT-NMA is feasible and safe in an ambulatory
setting.
OS for high risk NDMM and RRMM at 5 years of 61% and
53%, respectively, are higher than that achievable with
conventional therapy.
GvHD and relapse remain major obstacles warranting
further study.
Sustained MRD negativity would suggest the likelihood of
long-term disease control in a significant proportion of
patients
27. Conclusion
Tandem ASCT-NMA should be considered for
appropriately selected MM patients with a HLA
matched donor in the era of novel therapies
28. Acknowledgements
Myeloma Programme
Dr Anna Kalff
DrTrishWalker
Dr Jay Hocking
Dr Krystal Bergin
Daniela Klarica
John Coutsouvelis
SCT Programme
Dr Sharon Avery
Dr Sush Patil
A/Prof David Curtis
Dr Anish Puliyayil
Jenny Muirhead
Dr Tongted Das – chimaerism
Tina Pham - CTU
Gerri Bollard – CTU
Dr Susan Morgan - MRD
Geelong Hospital
A/Prof Phil Campbell
Dr David Kipp
Editor's Notes
Includes all deferred patients regardless of whether they had an initial ASCT
Includes all deferred patients regardless of whether they had an initial ASCT
Includes all deferred patients regardless of whether they had an initial ASCT